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Background             
 
Clopidogrel is indicated for the prevention of thrombotic complications in infants (aged 0 to 12 months) 
undergoing catheterization and device implant procedures due to congenital heart defects. Clopidogrel 
requires cytochrome P450 (CYP) 2C19 for conversion to the active metabolite (Fig 1). However, CYP2C19 
levels in infants do not reach adult levels until >6 months of age (Fig 2)1. It is therefore surprising that a 
0.2 mg/kg/day clopidogrel dose in infants achieves platelet inhibition comparable to that observed in 
adults on 75 mg/day (~1 mg/kg/day)2. A safe and efficacious dose of clopidogrel in infants is still unknown. 
This study aims to compare clopidogrel in vivo clearance between infants and adults, and determine the 
mechanism that could explain the difference in potency of clopidogrel in these two populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods            
 
Comparison of in vitro average intrinsic clearance via a time dependent curve 
Infant (age three and five months) and pooled adult (>18 years) human liver microsomes, prepared from 
liver tissue, were purchased from XenoTech LLC (Lenexa, KS). Microsomes were incubated with 50 M 
clopidogrel, NADPH (1 mM) and MgCl2 (3 mM) in phosphate buffer (pH 7.4) at 37°C. At various time points 
(0, 2, 5 and 10 minutes), 100 L aliquots were quenched with 300 L methanol (to precipitate proteins) 
containing diclofenac (20 M) as an internal standard, and centrifuged at 10,000g for 15 minutes. 
Supernatants containing clopidogrel were analyzed for the percent of parent drug remaining using high 
performance liquid chromatography (HPLC) with a UV detector operating at a wavelength of 235 nm. The 
intrinsic clearance was calculated by dividing the percent of parent drug remaining by the incubation time 
Figure 1. Activation of clopidogrel to its active metabolite via 
CYP2C19. 
 
Figure 2. CYP2C19 ontogeny in infants. Estimated gestational age 
(EGA) and postnatal age (PNA). 
 
and the milligrams of protein in the incubation. All measurements were done in triplicate. The average 
intrinsic clearance was then compared between the three month, five month, and pooled adult 
microsomes. 
 
Comparison of in vivo average intrinsic clearance via a concentration dependent curve 
Adult pooled microsomes were incubated with varying concentrations of clopidogrel (10 to 100 M), 
NADPH (1 mM) and MgCl2 (3 mM) in phosphate buffer (pH 7.4) at 37°C. After a 10 minute incubation 
period (determined by data shown in Fig 3), 100 L aliquots were quenched with 300 L methanol (to 
precipitate proteins) containing diclofenac (20 M) as an internal standard, and centrifuged at 10,000g 
for 15 minutes. Supernatants containing clopidogrel were analyzed for amount of parent drug remaining 
using HPLC with a UV detector operating at a wavelength of 235 nm. All measurements were done in 
triplicate. Subtracting the quantity of parent drug remaining from the initial amount enables 
determination of metabolite amount and subsequent formation rate. Hepatic intrinsic clearance and 
activation of clopidogrel can then be calculated by dividing Vmax by Km, and in vivo  clearance of clopidogrel 
can be determined by multiplying the hepatic intrinsic clearance by scaling factors (microsomal protein 
per gram of liver X liver weight (g)/body weight (kg)) (Fig 4). 
 
HPLC method 
The HPLC mobile phase consisted of 50% water containing 0.1% formic acid and 50% acetonitrile 
containing 0.1% formic acid. 
 
 
 
 
 
 
 
 
Results              
 
In vitro average intrinsic clearance 
Methods described previously were done in triplicate, and the n=1 measurements are represented in 
figures 5-7. Mean intrinsic clearances for adult, three month, and five month microsomes are shown in 
figure 8.  
Figure 3. HPLC data showing unchanged parent drug 
(clopidogrel) over 60 minutes. Ten minutes was selected as the 
incubation period for clopidogrel metabolism as this was within 
the linear range of clopidogrel disappearance. 
Figure 4. Calculation of in vivo intrinsic clearance. 
 
  
 
 
 
In vivo average intrinsic clearance 
The mean clopidogrel active metabolite formation rate at varying clopidogrel concentrations is shown in 
figure 9. The amount of clopidogrel remaining after metabolism of the 10 M clopidogrel incubation 
sample was unable to be detected by the HPLC method. Because the Km for clopidogrel is ~23.13, the 
amount of clopidogrel remaining after metabolism of the 10 M clopidogrel incubation is a necessary data 
point to calculate the Km and Vmax. As such, the in vivo average intrinsic clearance was unable to be 
determined. 
Figure 5. HPLC data showing the percent of parent drug 
(clopidogrel) remaining after metabolism with adult pooled 
microsomes over ten minutes. This represents n=1 out of 
measurements taken in triplicate. 
Figure 6. HPLC data showing the percent of parent drug 
(clopidogrel) remaining after metabolism with microsomes from 
a three month old infant over ten minutes. This represents n=1 
out of measurements taken in triplicate. 
Figure 7. HPLC data showing the percent of parent drug 
(clopidogrel) remaining after metabolism with microsomes from 
a five month old infant over ten minutes. This represents n=1 out 
of measurements taken in triplicate. 
Figure 8. Average intrinsic clearance for adult, three month, and 
five month samples. (Mean ± SD; n=3).  
 
 
Discussion             
 
When calculating the percent of clopidogrel remaining, two assumptions were made: 1) all of the 
clopidogrel metabolized was metabolized to the active metabolite, and 2) the conversion of clopidogrel 
to the active metabolite was mediated by CYP2C19 and CYP3A4. These assumptions were made with 
confidence because human liver microsomes are prepared in such a way so as not to contain the esterases 
which are responsible for clopidogrel degradation to the inactive metabolite.  
 
One limitation of the study is that the HPLC method used was not sensitive enough to detect the amount 
of clopidogrel remaining after metabolism of the 10 M incubation sample. Because of this sensitivity 
limitation, we were unable to determine Km, Vmax, and thus in vivo intrinsic clearance. Future directions 
may include measures to increase sensitivity, such as concentrating samples prior to HPLC injection, or 
utilizing a more sensitive instrument. Another limitation of the study was that only three month and five 
month old microsomes were used. Future studies may benefit by including more microsomal samples, 
encompassing a wider age range of infant microsomes. 
 
Based on CYP2C19 ontogeny in infants, one may expect the intrinsic clearance (and thus activation) of 
clopidogrel to be slower in infants relative to adults. However, it is known that infants have a much lower 
dose requirement for clopidogrel, in order to achieve the same level of platelet inhibition as that of adults. 
Based on the lower dose requirement, one alternative explanation may be that the metabolism of 
clopidogrel to the active metabolite is faster in infants and thus the intrinsic clearance would be higher. 
The objective of this study was to determine whether or not metabolism contributes to the increased 
potency of clopidogrel in infants. Because the intrinsic clearance of clopidogrel in 3 month and 5 month 
microsomes was slower than that of adults, we can conclude that a mechanism other than metabolism 
contributes to the increased potency of clopidogrel in infants. Other potential mechanisms to be explored 
include but are not limited to differences in platelet reactivity, esterase expression or activity, renal 
excretion of the active metabolite, or protein binding. 
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Figure 9. Clopidogrel active metabolite formation 
rate at varying concentrations. (Mean ± SD; n=3). 
